DAPAFORD M

DAPAFORD M

Dapagliflozin 10 mg + Metformin 500 mg

Uses:

  • Management of type 2 diabetes mellitus in adults to improve blood sugar control
  • Helps reduce the risk of hospitalization for heart failure in patients with type 2 diabetes and cardiovascular risk
  • May aid in weight reduction and improved glycemic control when diet and exercise alone are insufficient

DAPAFORD M

(Dapagliflozin + Metformin)

Dual Glycemic + Renal Protection Therapy

PRODUCT INTRODUCTION

Brand Name: DAPAFORD M
Composition:

  • Dapagliflozin
  • Metformin

Category: Combination OHA with Renal Benefit

 CLINICAL BACKGROUND

Most Type 2 Diabetes patients:

  • Start on Metformin
  • Develop progressive renal risk
  • Require additional renal protection

👉 DAPAFORD M combines glycemic base therapy + nephroprotection.

MODE OF ACTION

Metformin:

  • Reduces hepatic glucose production
  • Improves insulin sensitivity

Dapagliflozin:

  • Reduces glucose reabsorption
  • Protects kidney via hemodynamic mechanism

Combined Benefit:

✔ Strong HbA1c reduction
✔ Renal protection
✔ CV risk reduction

INDICATIONS

  • Type 2 Diabetes uncontrolled on Metformin
  • Diabetic nephropathy
  • Albuminuria
  • Obese diabetic patients

DOSAGE

As prescribed
Usually once or twice daily depending on strength

FAB

🔹 Feature

Dual combination tablet

🔹 Advantage

Glycemic + Renal + CV protection

🔹 Benefit

Comprehensive diabetes management

USP

✔ Single tablet compliance
✔ Renal-protective add-on
✔ Weight neutral to reducing
✔ Cardiometabolic benefit

 SAFETY PROFILE

  • Monitor renal function
  • Watch for UTI
  • Avoid in severe renal failure
  • Metformin contraindicated in advanced renal impairment

TORGIVE 10 / 20

(Torsemide 10 mg / 20 mg)

Advanced Loop Diuretic Therapy for Cardio–Renal Patients

 PRODUCT INTRODUCTION

Brand Name: TORGIVE 10 / 20
Composition: Torsemide 10 mg / 20 mg
Category: Loop Diuretic

CLINICAL BACKGROUND (FOR MR UNDERSTANDING)

In CKD & Heart Failure patients:

  • Fluid retention common
  • Peripheral edema
  • Pulmonary congestion
  • Hypertension worsens
  • Cardiac workload increases

👉 Proper diuresis improves outcomes.

Compared to Furosemide, Torsemide offers:

  • Better oral bioavailability
  • Longer duration
  • More predictable effect

 MODE OF ACTION (MOA)

  • Acts on Thick Ascending Limb of Loop of Henle
  • Inhibits Na⁺/K⁺/2Cl⁻ transporter
  • Promotes sodium & water excretion
  • Reduces preload & afterload

Clinical Effects:

✔ Reduces edema
✔ Lowers blood pressure
✔ Improves heart failure symptoms
✔ Decreases fluid overload in CKD

 INDICATIONS

  • Congestive Heart Failure
  • CKD with fluid overload
  • Nephrotic syndrome
  • Resistant hypertension
  • Peripheral edema

 DOSAGE

  • TORGIVE 10 mg – Mild to moderate edema
  • TORGIVE 20 mg – Severe edema / CHF

Once daily dosing preferred
As directed by physician

 

 FEATURE – ADVANTAGE – BENEFIT (FAB)

🔹 Feature

High oral bioavailability loop diuretic

🔹 Advantage

More predictable diuretic response vs furosemide

🔹 Benefit

Better symptom control & fewer hospitalizations

USP

✔ Longer duration of action
✔ Better absorption than furosemide
✔ Effective in CKD fluid overload
✔ Once daily convenience
✔ Useful in resistant edema

 

 SAFETY PROFILE

  • Hypokalemia
  • Hypotension
  • Dehydration
  • Monitor electrolytes
  • Use cautiously in severe renal impairment
Scroll to Top